Opioid-Induced Constipation (OIC) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Opioid-Induced Constipation (OIC) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Abstract
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.
Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Content
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Opioid-Induced Constipation (OIC) - Overview
Opioid-Induced Constipation (OIC) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opioid-Induced Constipation (OIC) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
BioGaia Pharma AB
Mallinckrodt Plc
PegBio Co Ltd
Shanghai Hanmai Biomedical Technology Co Ltd
Shionogi & Co Ltd
Yuhan Corp
Opioid-Induced Constipation (OIC) - Drug Profiles
BGP-345A - Drug Profile
Product Description
Mechanism Of Action
History of Events
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
History of Events
M-02 - Drug Profile
Product Description
Mechanism Of Action
naldemedine tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
PB-1902 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Opioid-Induced Constipation (OIC) - Dormant Projects
Opioid-Induced Constipation (OIC) - Discontinued Products
Opioid-Induced Constipation (OIC) - Product Development Milestones
Featured News & Press Releases
Jan 26, 2022: BioGaia Pharma announces first patient enrolled in phase II clinical study evaluating BGP345A for the treatment of opioid induced constipation (OIC-1)
May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week
Dec 30, 2014: Sucampo Announces Acceptance of New Drug Submission for AMITIZA (lubiprostone) by Health Canada
Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting
Sep 29, 2014: Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA (lubiprostone) for Chronic Idiopathic Constipation
Jul 23, 2014: Sucampo Announces Publication of NICE Recommendation for AMITIZA (Lubiprostone)
Jul 07, 2014: Swissmedic Approves AMITIZA (Lubiprostone) for the Treatment of Opioid-Induced Constipation
Jun 17, 2014: AMITIZA (Lubiprostone) Receives NICE Recommendation
Jun 12, 2014: Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting's Vote
May 06, 2014: Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Journal
May 01, 2014: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences
Apr 25, 2014: Sucampo Pharma To Present Preclinical Data For Lubiprostone at Experimental Biology Conference 2014
Mar 12, 2014: Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
Oct 11, 2013: Sucampo Announces Presentation of Results on AMITIZA in Opioid-Induced Constipation at Two Upcoming Scientific Conferences
Oct 08, 2013: Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Opioid-Induced Constipation (OIC) - Pipeline by BioGaia Pharma AB, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Mallinckrodt Plc, 2022
Opioid-Induced Constipation (OIC) - Pipeline by PegBio Co Ltd, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Shanghai Hanmai Biomedical Technology Co Ltd, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Yuhan Corp, 2022
Opioid-Induced Constipation (OIC) - Dormant Projects, 2022
Opioid-Induced Constipation (OIC) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.
Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Opioid-Induced Constipation (OIC) - Overview
Opioid-Induced Constipation (OIC) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opioid-Induced Constipation (OIC) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
BioGaia Pharma AB
Mallinckrodt Plc
PegBio Co Ltd
Shanghai Hanmai Biomedical Technology Co Ltd
Shionogi & Co Ltd
Yuhan Corp
Opioid-Induced Constipation (OIC) - Drug Profiles
BGP-345A - Drug Profile
Product Description
Mechanism Of Action
History of Events
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
History of Events
M-02 - Drug Profile
Product Description
Mechanism Of Action
naldemedine tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
PB-1902 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Opioid-Induced Constipation (OIC) - Dormant Projects
Opioid-Induced Constipation (OIC) - Discontinued Products
Opioid-Induced Constipation (OIC) - Product Development Milestones
Featured News & Press Releases
Jan 26, 2022: BioGaia Pharma announces first patient enrolled in phase II clinical study evaluating BGP345A for the treatment of opioid induced constipation (OIC-1)
May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week
Dec 30, 2014: Sucampo Announces Acceptance of New Drug Submission for AMITIZA (lubiprostone) by Health Canada
Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting
Sep 29, 2014: Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA (lubiprostone) for Chronic Idiopathic Constipation
Jul 23, 2014: Sucampo Announces Publication of NICE Recommendation for AMITIZA (Lubiprostone)
Jul 07, 2014: Swissmedic Approves AMITIZA (Lubiprostone) for the Treatment of Opioid-Induced Constipation
Jun 17, 2014: AMITIZA (Lubiprostone) Receives NICE Recommendation
Jun 12, 2014: Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting's Vote
May 06, 2014: Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Journal
May 01, 2014: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences
Apr 25, 2014: Sucampo Pharma To Present Preclinical Data For Lubiprostone at Experimental Biology Conference 2014
Mar 12, 2014: Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
Oct 11, 2013: Sucampo Announces Presentation of Results on AMITIZA in Opioid-Induced Constipation at Two Upcoming Scientific Conferences
Oct 08, 2013: Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Opioid-Induced Constipation (OIC) - Pipeline by BioGaia Pharma AB, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Mallinckrodt Plc, 2022
Opioid-Induced Constipation (OIC) - Pipeline by PegBio Co Ltd, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Shanghai Hanmai Biomedical Technology Co Ltd, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, 2022
Opioid-Induced Constipation (OIC) - Pipeline by Yuhan Corp, 2022
Opioid-Induced Constipation (OIC) - Dormant Projects, 2022
Opioid-Induced Constipation (OIC) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Opioid-Induced Constipation (OIC), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Related Report
